Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8147292 | 0.92 | GSK3B (0.80) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| SCHEMBL8142278 | 0.90 | GSK3B (0.74) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| SCHEMBL12762594 | 0.89 | GSK3B (0.86) | GSK3BSMN1; SMN2CDK1CCNB2CCNB1 | |
| SCHEMBL8138094 | 0.87 | GSK3B (1.00) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| Hydrochloric Acid SCHEMBL1514124 | 0.87 | GSK3B (0.98) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| SCHEMBL12762597 | 0.87 | GSK3B (0.87) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| SCHEMBL12835842 | 0.85 | GSK3B (0.72) | GSK3BHPGDCDK1CCNB2CCNB1 | |
| Hydrochloric Acid SCHEMBL1514127 | 0.84 | GSK3B (0.71) | GSK3BHPGDCDK1CCNB2CCNB1 | |
| SCHEMBL12762583 | 0.84 | GSK3B (0.66) | GSK3BCDK1CCNB2CCNB1RPS6KB1 | |
| SCHEMBL1514107 | 0.83 | GSK3B (0.81) | GSK3BCDK1CCNB2CCNB1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-03 | — | — | US | disclosed |
| US-8476267-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8476267-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2176264-B1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES FOR TREATING HEMATOLOGICAL DISORDERS | BAYER IP GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2009007029-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885SMN1; SMN2 1522/4885NPC1 2935/4885 |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885SMN1; SMN2 1522/4885NPC1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.